2018晚期NSCLC进展总结讲义教材.pptVIP

力比泰用于EGFR突变患者的疗效 Yang CH, et al. 2012 ASCO Abstract LBA7500. Scagliotti GV, et al. J Clin Oncol. 2008;26(21):3543-51. 2% Progression-free survival (probability) 1.0 0.8 0.6 0.4 0.2 0.0 Progression-free survival (months) 0 3 6 9 12 15 18 21 24 27 22% Gem/cis Pem/cis LUX-Lung 6 LUX-Lung 3 Gem/cis (n=122) Pem/cis (n=115) Median PFS (months) 5.6 6.9 力比泰联合及单药治疗ALK+患者的疗效 0 6 12 18 24 30 36 0 0.2 0.2 0.6 0.8 1 0 6 12 18 24 30 36 0 0.2 0.2 0.6 0.8 1 0 6 12 18 24 30 36 0 0.2 0.2 0.6 0.8 1 0 6 12 18 24 30 36 0 0.2